A detailed history of Advisor Group Holdings, Inc. transactions in Zai Lab LTD stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 11 shares of ZLAB stock, worth $339. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11
Previous 75 85.33%
Holding current value
$339
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$13.72 - $21.55 $878 - $1,379
-64 Reduced 85.33%
11 $0
Q1 2024

May 10, 2024

SELL
$15.95 - $26.8 $95 - $160
-6 Reduced 7.41%
75 $1,000
Q4 2023

Feb 12, 2024

SELL
$22.97 - $30.58 $2,297 - $3,058
-100 Reduced 55.25%
81 $2,000
Q3 2023

Nov 13, 2023

BUY
$22.72 - $31.49 $976 - $1,354
43 Added 31.16%
181 $4,000
Q1 2023

May 12, 2023

SELL
$30.21 - $48.1 $1,782 - $2,837
-59 Reduced 29.95%
138 $4,000
Q4 2022

Feb 10, 2023

BUY
$22.28 - $38.71 $1,247 - $2,167
56 Added 39.72%
197 $6,000
Q3 2022

Nov 14, 2022

SELL
$34.2 - $51.69 $3,420 - $5,169
-100 Reduced 41.49%
141 $5,000
Q2 2022

Aug 10, 2022

BUY
$23.14 - $49.68 $46 - $99
2 Added 0.84%
241 $8,000
Q1 2022

May 04, 2022

SELL
$27.77 - $64.4 $3,915 - $9,080
-141 Reduced 37.11%
239 $9,000
Q3 2021

Nov 05, 2021

BUY
$105.0 - $178.37 $2,415 - $4,102
23 Added 6.44%
380 $40,000
Q2 2021

Aug 02, 2021

BUY
$125.11 - $180.0 $6,255 - $9,000
50 Added 16.29%
357 $63,000
Q1 2021

May 13, 2021

BUY
$126.27 - $191.71 $16,541 - $25,114
131 Added 74.43%
307 $41,000
Q4 2020

Feb 10, 2021

BUY
$81.94 - $135.34 $1,147 - $1,894
14 Added 8.64%
176 $23,000
Q3 2020

Nov 12, 2020

BUY
$73.3 - $89.48 $5,570 - $6,800
76 Added 88.37%
162 $12,000
Q2 2020

Aug 14, 2020

SELL
$48.82 - $82.53 $1,903 - $3,218
-39 Reduced 31.2%
86 $7,000
Q1 2020

May 18, 2020

BUY
$39.1 - $62.9 $4,887 - $7,862
125 New
125 $7,000

Others Institutions Holding ZLAB

About Zai Lab Ltd


  • Ticker ZLAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,908,704
  • Market Cap $3.02B
  • Description
  • Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...
More about ZLAB
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.